Theravance Biopharma, Inc. (FRA:0TB)
Germany · Delayed Price · Currency is EUR | Market Cap | 707.28M +73.1% |
| Revenue (ttm) | 95.21M +68.2% |
| Net Income | 99.34M |
| EPS | 1.92 |
| Shares Out | n/a |
| PE Ratio | 7.12 |
| Forward PE | 32.29 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 13.30 |
| Previous Close | 13.50 |
| Day's Range | 13.30 - 13.30 |
| 52-Week Range | 7.95 - 17.50 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 3, 2026 |
About Theravance Biopharma
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. fo... [Read more]
News
Theravance Biopharma reports Q1 EPS (10c) vs. (17c) last year
Reports Q1 revenue $17.7M, consensus $17.45M. “We delivered strong financial performance in the first quarter, reinforcing the quality of our commercial asset, our robust balance sheet and the importa...
Theravance Biopharma Earnings release: Q1 2026
Theravance Biopharma released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Theravance Biopharma Quarterly report: Q1 2026
Theravance Biopharma has published its Q1 2026 quarterly earnings report on May 7, 2026.
Theravance Biopharma, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update
YUPELRI ® Collaboration Revenue increased 15% year-over-year 1 , from $15.4 million to $17.7 million, driven by continued Net Sales growth and improved operating leverage All Hatch-Waxman litigation r...
Theravance Biopharma Proxy statement: Proxy filing
Theravance Biopharma filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Theravance Biopharma price target raised to $17 from $14 at B. Riley
B. Riley raised the firm’s price target on Theravance Biopharma (TBPH) to $17 from $14 and keeps a Neutral rating on the shares. The final generic settlement with Mankind (MNKD)…
Theravance Biopharma price target raised to $15 from $13 at TD Cowen
TD Cowen raised the firm’s price target on Theravance Biopharma (TBPH) to $15 from $13 and keeps a Hold rating on the shares. The firm said they reported Q4 results…
Theravance Biopharma reports Q4 EPS $1.15, consensus $1.10
Reports Q4 revenue $45.891M, consensus $50.7M. “We ended 2025 on a positive note from a financial perspective, achieving another record quarter of non-GAAP profitability, hitting a new all-time high f...
Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Organizational restructuring and cost reduction plan following results of the Phase 3 CYPRESS study of ampreloxetine are underway; expected to generate $60 - $70 million of annualized cash flow starti...
Theravance Biopharma Annual report: Q4 2025
Theravance Biopharma has published its Q4 2025 annual report on March 19, 2026.
Theravance Biopharma Earnings release: Q4 2025
Theravance Biopharma released its Q4 2025 earnings on March 19, 2026, summarizing the period's financial results.
Theravance Biopharma Slides: Corporate presentation
Theravance Biopharma has posted slides in relation to its latest quarterly earnings report, which was published on March 7, 2026.
Theravance Biopharma downgraded to Perform from Outperform at Oppenheimer
Oppenheimer analyst Trevor Allred downgraded Theravance Biopharma (TBPH) to Perform from Outperform.
Theravance Biopharma downgraded at Oppenheimer after ampreloxetine miss
As previously reported, Oppenheimer downgraded Theravance Biopharma (TBPH) to Perform from Outperform after the company recently announced that the Phase 3 CYPRESS study did not meet its primary endpo...
Theravance Biopharma price target lowered to $15 from $27 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Theravance Biopharma (TBPH) to $15 from $27 and keeps a Buy rating on the shares. The firm cites the CYPRESS data “disappointment”…
Theravance Biopharma downgraded to Neutral from Buy at B. Riley
B. Riley downgraded Theravance Biopharma (TBPH) to Neutral from Buy with a price target of $14, down from $28. The company reported that the Phase 3 CYPRESS study evaluating ampreloxetine…
Theravance Biopharma price target lowered to $21 from $40 at BTIG
BTIG lowered the firm’s price target on Theravance Biopharma (TBPH) to $21 from $40 and keeps a Buy rating on the shares after removing ampreloxetine from the firm’s model. The…
Theravance Biopharma falls 28% to $13.55 in pre-market trading
In pre-market trading, shares of Theravance Biopharma (TBPH) are down 28% to $13.55 after the company announced that the Phase 3 CYPRESS study did not meet its primary endpoint. In…
Theravance Biopharma implements cost reduction actions after study results
Theravance Biopharma (TBPH) has decided to wind down the ampreloxetine program after topline results from the Phase 3 CYPRESS study evaluating the efficacy and safety of ampreloxetine in patients with...
Theravance Biopharma trading resumes
08:50 EST Theravance Biopharma (TBPH) trading resumes
Theravance Biopharma says Phase 3 CYPRESS Study did not meet primary endpoint
08:36 EST Theravance Biopharma (TBPH) says Phase 3 CYPRESS Study did not meet primary endpoint
Theravance Biopharma winding down ampreloxetine program after Phase 3 results
Theravance Biopharma (TBPH) announced topline results from the Phase 3 CYPRESS study evaluating the efficacy and safety of ampreloxetine in patients with symptomatic neurogenic orthostatic hypotension...
Theravance plans strategic review, including possible sale, after drug trial failure
Theravance Biopharma said on Tuesday it is initiating a strategic review, including a possible sale of the company, after its experimental drug to treat a type of blood pressure disorder failed to...
Theravance Biopharma trading halted, news pending
08:26 EST Theravance Biopharma (TBPH) trading halted, news pending
Theravance Biopharma Reports Phase 3 CYPRESS Study Did Not Meet Primary Endpoint; Board Accelerates Strategic Review and Announces Cost Reduction Actions
Phase 3 CYPRESS study did not meet the primary endpoint , the OHSA Composite Score, a patient reported outcome (PRO) Cash of $326.5 million at Q4 2025 (no debt); approximately $400 million expected at...